Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Hldgs is a promising investment opportunity due to a strong product portfolio and favorable market conditions. The recent 20% expansion of the sales force and positive legal developments have improved the revenue outlook for the company, with forecasted sales of $1.11B in 2026 and peak sales of $1.29B in 2029. Risks to the outlook include potential generic competition and legal challenges, but potential positive outcomes from clinical development of other drug candidates and improved patient adherence through next-generation treatments provide additional upside potential for the company.

Bears say

Harmony Biosciences Hldgs is currently facing challenges with its drug candidates in the pipeline as they still require further clinical trials and approvals, and its current commercial product, WAKIX, only holds a small market share. With a limited product portfolio, the company's financial performance is expected to be volatile and unpredictable, making it a risky investment. Additionally, the stock's recent significant increase may not be sustainable in the long term, as it may not reflect the company's underlying fundamental weaknesses.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.